Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.60 |
| ▸ | CTSL | P07711 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | MAX | P61244 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | RXRG | P48443 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722311 | 0.89 | CTSV (0.54) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL8902301 | 0.86 | CTSV (0.60) | CTSVCTSLMAPTABCB1MEN1 | |
| SCHEMBL28257932 | 0.85 | CTSV (0.63) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL9313845 | 0.84 | CTSV (0.50) | CTSVCTSLMAPTMYCMAX | |
| SCHEMBL3112448 | 0.83 | RXRA (0.59) | CTSVCTSLMAPTMCL1RXRA | |
| SCHEMBL4647237 | 0.82 | POLB (0.48) | CTSVCTSLMAPTABCB1MEN1 | |
| SCHEMBL8316504 | 0.81 | CTSV (0.61) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL8009518 | 0.81 | MAPT (0.52) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL7116860 | 0.80 | POLB (0.56) | CTSVCTSLMAPTABCB1MEN1 | |
| SCHEMBL750245 | 0.80 | CTSV (0.63) | CTSVCTSLMAPTMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102482256-B | N-substituted cyclic amino derivatives | DAINIPPON SUMITOMO PHARMA CO | 2014-11-26 | — | — | CN | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| CN-102482256-A | N-substituted cyclic amino derivatives | DAINIPPON SUMITOMO PHARMA CO | 2012-05-30 | — | — | CN | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-2447264-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | CTSV 2290/4885CTSL 1267/4885MAPT 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.